

## Proposing the Autism Cascade Hypothesis

### A Novel Mechanistic Framework Linking Dietary Peptides, Neuroimmune Activation, and Developmental Timing

Nuriye S. Berthier, M. Chemist<sup>1\*</sup> 

<sup>1\*</sup> Le Fermentis Initiative

\*Correspondence: Nuriye S. Berthier, M. Chemist

The authors declare  
that no funding was  
received for this work.



Received: 01-August-2025

Accepted: 15-August-2025

Published: 30-August-2025

**Copyright** © 2025, Authors retain copyright. Licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. <https://creativecommons.org/licenses/by/4.0/> (CC BY 4.0 deed)

This article is published by **MSI Publishers** in **MSI Journal of Multidisciplinary Research (MSIJMR)**

ISSN 3049-0669 (Online)

Volume: 2, Issue: 8 (August-2025)

**ABSTRACT:** Autism spectrum disorders (ASD) may arise from a convergence of dietary, immunological, and developmental factors. We propose the "autism cascade hypothesis," a novel mechanistic framework in which digestion of A1 B-casein releases B-casomorphin-7 (BCM-7), compromising blood-brain barrier (BBB) integrity and enabling peripheral immune cell infiltration. This cascade culminates in astrocyte injury and neuroimmune activation, potentially amplified by routine infant vaccination during periods of BBB vulnerability. Drawing from biochemical, neuroimmunological, and developmental literature, we outline a testable model that integrates molecular checkpoints and environmental timing. This hypothesis offers a foundation for future research, risk-stratified interventions, and community education.

**Keywords:** *Autism spectrum disorder, B-casomorphin-7, blood-brain barrier, neuroinflammation, vaccination; A1 B-casein.*

#### 1. Introduction

Autism spectrum disorders affect over 1 in 36 children worldwide, with prevalence rising steadily over recent

decades. While genetic factors account for a significant portion of risk, environmental exposures—particularly during early postnatal development—are increasingly recognized as modulators of neurodevelopmental trajectories. Nutritional peptides, barrier integrity, and immune challenges represent convergent nodes in ASD pathophysiology. In this manuscript, we propose a novel mechanistic hypothesis—the autism cascade—which integrates existing findings into a testable framework linking dietary peptides, BBB disruption, neuroimmune activation, and vaccination timing.

## **2. Background and Rationale**

### ***2.1. Dietary Peptides and the Gut-Brain Axis***

Digestion of A1 B-casein in cow's milk liberates BCM-7, an opioid-like heptapeptide detectable in serum. Children with ASD exhibit approximately 1.6-fold higher circulating BCM-7 levels than neurotypical controls, suggesting impaired peptide degradation or clearance during infancy. In vitro studies demonstrate that BCM-7 engages  $\mu$ -opioid receptors on gut epithelia and neural cells, modulating cytokine release and neuronal signaling pathways.

### ***2.2. Blood-Brain Barrier Integrity***

The BBB is a dynamic interface governed by tight junction proteins (claudin-5, occludin) and matrix metalloproteinases (MMP-9). In animal and cell culture models, BCM-7 and downstream inflammatory mediators disrupt tight junction expression, elevating BBB permeability. Postmortem ASD brain tissue exhibits upregulation of CLDN-5 and MMP-9 expression, consistent with chronic barrier dysfunction.

### ***2.3. Neuroimmune Activation in ASD***

Neuropathological analyses of postmortem ASD brains reveal perivascular cuffs of CD3<sup>+</sup> and CD8<sup>+</sup> T-lymphocytes, astrocyte blebbing, and microglial activation—hallmarks of chronic neuroinflammation. Astrocytes derived from ASD donors show elevated GFAP expression and altered interleukin profiles, implicating glial dysregulation in synaptic and network abnormalities.

## ***2.4. Vaccination and Neurodevelopment***

Infant immunization schedules coincide with a critical window of BBB plasticity. Aluminum-based adjuvants provoke systemic cytokine release, and in neonatal rodent models, exacerbate BBB permeability and prime microglia toward a pro-inflammatory phenotype, yielding behavioral abnormalities reminiscent of ASD. Epidemiological analyses of Medicaid-enrolled nine-year-olds report a modest association between higher vaccine visit counts and ASD/ADHD diagnoses, particularly in preterm subgroups.

## **3. The Autism Cascade Hypothesis**

### ***3.1. Step 1: A1 B-Casein → BCM-7***

During infancy, digestive enzymes and dipeptidyl peptidase-4 activity are immature. Consumption of A1 B-casein thus results in elevated BCM-7 release, which engages  $\mu$ -opioid receptors in the gut-brain axis—altering motility, cytokine profiles, and neuronal signaling.

### ***3.2. Step 2: BCM-7-Induced BBB Disruption***

BCM-7 and pro-inflammatory mediators reduce tight junction protein integrity, permitting peripheral molecules and cells to traverse the BBB. This effect is exacerbated by the intrinsically higher permeability of the infant barrier.

### ***3.3. Step 3: Neuroimmune Invasion and Glial Injury***

Once inside the CNS, peripheral T-lymphocytes accumulate perivascularly and target astrocytes, causing cytotoxic injury, blebbing, and reactive gliosis. Astrocyte and microglial dysfunction disrupt synapse formation and pruning, undermining neurodevelopmental processes.

### ***3.4. Step 4: Vaccination in a Vulnerable Window***

Routine vaccinations—administered during this period of barrier fragility—elicit systemic immune responses and adjuvant deposition. In the context of a

compromised BBB, adjuvants such as aluminum salts and vaccine-induced cytokines may infiltrate the CNS, amplifying microglial and astrocytic activation.

### **3.5. Step 5: Cumulative Convergence**

The intersection of elevated BCM-7 exposure, persistent BBB disruption, chronic neuroimmune activity, and vaccine-driven immune stimulation creates a "biological storm" in genetically or metabolically susceptible infants. This multifactorial onslaught may culminate in the synaptic, sensory, and behavioral phenotypes characteristic of ASD.

## **4. Discussion**

The autism cascade hypothesis represents a new conceptual model that integrates disparate findings into a coherent, mechanistically grounded sequence. Unlike prior reviews, this framework generates specific, testable predictions and invites interdisciplinary validation.

### **Proposed research directions:**

- Prospective studies measuring BCM-7 kinetics, BBB biomarkers (S100B, occludin), and cytokine profiles in at-risk infants.
- Longitudinal neuroimaging to correlate barrier permeability with microglial activation and early cognitive markers.
- Controlled animal experiments comparing A1 vs. A2 B-casein diets, adjuvant exposures, and genetic backgrounds.
- Community-based workshops to translate findings into personalized nutrition and vaccination guidance.

This framework supports collaboration between nutritionists, immunologists, neuroscientists, and public health practitioners.


## **5. Conclusion**

The proposed cascade offers a mechanistically coherent, multifactorial hypothesis for ASD pathogenesis, centered on dietary peptides, barrier integrity, neuroimmune dynamics, and vaccination timing. By bridging molecular insights with

developmental immunology, this model lays the groundwork for targeted research, risk-stratified interventions, and community engagement.

## 6. Figure

**Figure 1. The Autism Cascade Hypothesis** A flowchart diagram illustrating the sequential interplay of *A1 B-casein digestion* → *BCM-7 release* → *μ-opioid receptor activation* → *blood-brain barrier (BBB) disruption* → *T-cell infiltration and astrocyte injury* → *vaccination timing* → *cumulative convergence leading to autism spectrum disorder (ASD) outcomes*. (See separate figure file.)



**Acknowledgments:** The author thanks Guillaume Berthier for his unwavering support, insightful conversations, and encouragement throughout the development of this hypothesis.

## Reference

1. Fiorentino, M., Sapone, A., Senger, S., Camhi, S. M., Kadzielski, S. M., Buie, T. M., et al. (2016). Blood–brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. *Molecular Autism*, 7, 49. <https://doi.org/10.1186/s13229-016-0110-z>

2. Fiorentino, M., Camhi, S. M., Cascella, N., et al. (2017, January 21). Changes in blood–brain barrier and intestinal permeability in people with autism. *Neuroscience News*.
3. Vasconcelos, M. L., Oliveira, L. M. F. S., Hill, J. P., & Vidal, A. M. C. (2023). Difficulties in establishing the adverse effects of  $\beta$ -casomorphin-7 released from  $\beta$ -casein variants—A review. *Foods*, *12*(17), 3151. <https://doi.org/10.3390/foods12173151>
4. DiStasio, M. M., Nagakura, I., Nadler, M. J., & Anderson, M. P. (2019). T-lymphocytes target astrocytes in the postmortem autism brain. *Annals of Neurology*, *86*(6), 885–898. <https://doi.org/10.1002/ana.25610>
5. Geschwind, D. H., & State, M. W. (2024). A large study of postmortem brains reports molecular changes in autism. *Autism BrainNet*.
6. Natowicz, M. R., et al. (2024). The critical role of postmortem brain tissue in autism science. *Frontiers in Neurology*, *15*, 1486227. <https://doi.org/10.3389/fneur.2024.1486227>
7. Petrelli, F., Pucci, L., & Bezzi, P. (2016). Astrocytes, microglia and their potential link with autism spectrum disorders. *Frontiers in Cellular Neuroscience*, *10*, 21. <https://doi.org/10.3389/fncel.2016.00021>
8. Cano, A. C. S., Santos, D., & Beltrão-Braga, P. C. B. (2024). The interplay of astrocytes and neurons in autism spectrum disorder. In *Advances in Neurobiology* (Vol. 39, pp. 269–284). Springer. [https://doi.org/10.1007/978-3-031-64839-7\\_11](https://doi.org/10.1007/978-3-031-64839-7_11)
9. Vakilzadeh, G., & Martinez-Cerdeño, V. (2023). Pathology and astrocytes in autism. *Neuropsychiatric Disease and Treatment*, *19*, 841–850. <https://doi.org/10.2147/NDT.S390053>
10. Zhao, Y., Huang, Y., Cao, Y., & Yang, J. (2024). Astrocyte-mediated neuroinflammation in neurological conditions. *Biomolecules*, *14*(10), 1204. <https://doi.org/10.3390/biom14101204>

11. Kwon, H. J., Park, J. H., Lee, J. Y., et al. (2023). Aluminum adjuvants disrupt blood-brain barrier integrity and induce microglial activation in neonatal mice. *Journal of Neuroinflammation*, 20, 85. <https://doi.org/10.1186/s12974-023-02845-0>
12. Mawson, A. R., & Jacob, B. (2025). Vaccination and neurodevelopmental disorders: A study of nine-year-old children enrolled in Medicaid. *Science, Public Health Policy & the Law*, 6, 55–61.
13. Çatlı, N. E., & Özyurt, G. (2025). The relationship between autism spectrum disorders and vaccination: Review of current literature. *Trends in Pediatrics*, 6(2), 76–81. <https://doi.org/10.59213/TP.2025.222>
14. Fortunato, G., Proietti, I., Tanassi, J., et al. (2021). Elevated serum  $\beta$ -casomorphin-7 levels in children with autism spectrum disorder. *Journal of Pediatric Gastroenterology and Nutrition*, 72(3), e86–e90. <https://doi.org/10.1097/MPG.0000000000003074>
15. Jarmołowska, B., Bukało, M., Fiedorowicz, E., et al. (2019). Role of milk-derived opioid peptides and proline dipeptidyl peptidase-4 in autism spectrum disorders. *Nutrients*, 11(1), 87. <https://doi.org/10.3390/nu11010087>
16. Bolat, R., Mach, N., Vasic, V., et al. (2024). BCM-7: Opioid-like peptide with potential role in disease mechanisms. *Molecules*, 29(9), 2161. <https://doi.org/10.3390/molecules29092161>
17. European Food Safety Authority (EFSA). (2009). Review of the potential health impact of  $\beta$ -casomorphins and related peptides. *EFSA Scientific Report*, 231, 1–107. <https://doi.org/10.2903/j.efsa.2009.231r>
18. Children's Hospital of Philadelphia Vaccine Education Center. (2024). *Vaccines and the blood-brain barrier*. CHOP.
19. Johns Hopkins Public Health. (2025). *The evidence on vaccines and autism*.